HeimGLAXF • OTCMKTS
add
GSK plc
Við síðustu lokun
18,06 $
Árabil
16,80 $ - 23,00 $
Markaðsvirði
75,06 ma. USD
Meðalmagn
2,06 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
LON
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (GBP) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 8,01 ma. | -1,66% |
Rekstrarkostnaður | 5,02 ma. | 59,83% |
Nettótekjur | -58,00 m. | -103,96% |
Hagnaðarhlutfall | -0,72 | -104,01% |
Hagnaður á hvern hlut | 1,29 | 5,78% |
EBITDA | 1,62 ma. | -51,61% |
Virkt skatthlutfall | -1,56% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (GBP) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 3,21 ma. | -51,94% |
Heildareignir | 58,05 ma. | -4,62% |
Heildarskuldir | 44,60 ma. | -7,56% |
Eigið fé alls | 13,45 ma. | — |
Útistandandi hlutabréf | 4,08 ma. | — |
Eiginfjárgengi | 5,27 | — |
Arðsemi eigna | 2,87% | — |
Ávöxtun eigin fjár | 5,54% | — |
Peningaflæði
Breyting á handbæru fé
| (GBP) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | -58,00 m. | -103,96% |
Handbært fé frá rekstri | 2,15 ma. | -2,62% |
Reiðufé frá fjárfestingum | -731,00 m. | -48,88% |
Reiðufé frá fjármögnun | -1,24 ma. | 29,63% |
Breyting á handbæru fé | 149,00 m. | 927,78% |
Frjálst peningaflæði | 1,89 ma. | 40,47% |
Um
GSK plc is a British multinational pharmaceutical and biotechnology company with headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
GSK is the tenth largest pharmaceutical company and No. 294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck Sharp & Dohme.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of February 2024, it had a market capitalisation of £69 billion, the eighth largest on the London Stock Exchange.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Legacy products developed at GSK include several listed in the World Health Organization's List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine and zidovudine. Wikipedia
Framkvæmdastjóri
Stofnsett
27. des. 2000
Vefsvæði
Starfsfólk
70.212
